Susquehanna International Group, LLP Protagonist Therapeutics, Inc Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $724,980 - $1.02 Million	-21,500 Reduced 63.05%	12,600 $566,000
Q2 2024 Aug 15, 2024	SELL	$24.66 - $34.8 $397,026 - $560,280	-16,100 Reduced 32.07%	34,100 $1.18 Million
Q1 2024 May 07, 2024	BUY	$21.79 - $32.15 $361,714 - $533,690	16,600 Added 49.4%	50,200 $1.45 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $25,290 - $42,192	1,800 Added 5.66%	33,600 $770,000
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $3.12 Million - $4.43 Million	-187,200 Reduced 85.48%	31,800 $530,000
Q2 2023 Aug 11, 2023	BUY	$18.02 - $29.36 $1.36 Million - $2.21 Million	75,300 Added 52.4%	219,000 $6.05 Million
Q1 2023 May 16, 2023	SELL	$10.78 - $25.38 $169,246 - $398,466	-15,700 Reduced 9.85%	143,700 $3.31 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $425,408 - $645,626	57,800 Added 56.89%	159,400 $1.74 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $481,032 - $716,652	61,200 Added 151.49%	101,600 $856,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.02B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.